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Abstract  Molecular  markers  in  leukaemia  are  essential  to  diagnose,  establish  prognosis  fac-
tors and  determine  the  correct  treatment  of  patients;  therefore,  it  is  imperative  to  include
molecular biology  studies,  so  that,  combined  with  cytomorphology  and  immunophenotyping
studies, they  constitute  the  differential  diagnosis  of  these  neoplasias.  It  is  extremely  impor-
tant to  implement  a  panel  of  molecular  markers  that  allows  us  to  detect  oncogenes  derived
from chromosomal  translocations,  genes  derived  from  epigenetic  alterations  and  drug-resistant
genes.
A panel  of  molecular  markers  that  included  11  genes  derived  from  chromosomal  translocations
BCR-ABL  major  and  minor  breakpoints,  E2A-PBX1,  MLL-AF4,  TEL-AML1,  PML-RAR,  AML1-ETO
was standardised;  cancer  testis  antigens  (CTA)  derived  from  NY-ESO1  and  MAGE-A3  epige-
netic alterations  and  multi-drug-resistant  genes  ABCB1  and  ABCG2.  30  patients  diagnosed  with
leukaemia  from  Mexico’s  General  Hospital  (Hospital  General  de  Mexico)  were  included.  They
suffered  from  acute  lymphoblastic  leukaemia  (ALL)  and  acute  myeloblastic  leukaemia  (AML);
bone marrow  mononuclear  cells  were  used,  from  which  RNA  was  extracted  for  the  synthesis  of
 of  the  markers.  In  acute  lymphoblastic  leukaemia  (ALL),  BCR-ABL
r  30%  (3/10),  E2A-PBX1  10%  (1/10),  ABC-B1  80%  (8/10),  and  ABC-G2
ute  myeloblastic  leukaemia  (AML)  expressed  30%  PML-RAR  (3/10),cDNA and  RT-PCR  for  each
biomarkers  expressed  unde
60% (6/10).  Patients  with  ac∗ Corresponding author at: Dr. Balmis 148, Col. Doctores, Del. Cuauhtémoc, C.P. 06726, México, D.F., Mexico.
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40%  ABC-B1  (4/10),  and  10%  ABC-G2  (1/10).  Lastly,  in  patients  with  chronic  myeloid  leukaemia
(CML), BCR-ABL  was  over  100%  (10/10),  ABC-B1  20%  (2/10),  and  ABC-G2  50%  (5/10).  The  pres-
ence of  transcripts  from  chimeric  genes  minor  BCR-ABL  and  E2A-PBX1  in  ALL;  PML-RAR  in  AML;
and major  BCR-ABL  in  CML,  conﬁrms  the  importance  that  the  panel  of  molecular  markers  has
in strengthening  the  diagnosis  and  prognosis  of  these  conditions.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Published  by  Masson  Doyma  México
S.A. All  rights  reserved.
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Detección  y  análisis  de  biomarcadores  tumorales  como  fortalecimento  en  el
diagnóstico  de  leucemias  agudas  y  crónicas
Resumen  Los  marcadores  moleculares  en  leucemias  son  fundamentales  para  el  diagnóstico,
el establecimiento  de  factores  pronósticos  y  la  determinación  del  tratamiento  adecuado  para
los pacientes;  por  tanto  es  obligado  incluir  los  estudios  de  biología  molecular,  para  que  aunado
a los  de  citomorfología  e  Inmunofenotipo,  conformen  el  diagnóstico  diferencial  de  estas  neo-
plasias. Es  de  gran  importancia  implementar  un  panel  de  marcadores  moleculares  que  permita
detectar oncogenes  derivados  de  translocaciones  cromosómicas,  genes  derivados  de  cambios
epigenéticos  y  de  resistencia  genes  a  drogas.
Se estandarizó  un  panel  de  marcadores  moleculares  que  incluyeron  11  genes  derivados
de translocaciones  cromosómicas  BCR-ABL  rompimiento  mayor  y  menor,  E2A-PBX1,  MLL-AF4,
TEL-AML1,  PML-RAR,  AML1-ETO;  los  antígenos  testiculares  de  cáncer  (ATC)  derivados  de  cam-
bios epigenéticos  NY-ESO1  y  MAGE-A3  y  genes  de  resistencia  multidrogas  ABCB1  y  ABCG2.  Se
incluyeron 30  pacientes  con  diagnóstico  de  leucemia  del  Hospital  General  de  México,  de  los
tipos, leucemia  aguda  linfoblástica  (LAL)  y  mieloblástica  (LAM)  así  como  leucemia  mieloide
crónica (LMC);  se  utilizaron  células  mononucleares  de  médula  ósea,  a  las  cuales  se  les  extrajo
RNA para  la  posterior  síntesis  de  cDNA  y  RT-PCR  para  cada  uno  de  los  marcadores.  En  leucemia
linfoblástica  aguda  (LAL)  se  expresaron  los  biomarcadores  BCR-ABL  menor  30%  (3/10),  E2A-PBX1
10% (1/10),  ABC-B1  80%  (8/10),  y  ABC-G2  60%  (6/10).  Los  pacientes  con  leucemia  mieloblás-
tica aguda  (LAM)  expresaron  PML-RAR  30%  (3/10),  ABC-B1  40%  (4/10),  y  ABC-G2  10%  (1/10).
Finalmente,  en  pacientes  con  leucemia  mieloide  crónica  (LMC)  se  encontró  BCR-ABL  mayor
100% (10/10),  ABC-B1  20%  (2/10),  y  ABC-G2  50%  (5/10).  La  presencia  de  los  transcritos  de  los
genes quiméricos  BCR-ABL  menor  y  E2A-PBX1  en  LAL;  PML-RAR  en  LAM;  y  BCR-ABL  mayor  en
LMC, conﬁrma  la  importancia  del  panel  de  marcadores  moleculares  en  el  fortalecimiento  del
diagnóstico  y  pronóstico  para  dichos  padecimientos.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Publicado  por  Masson  Doyma  México
S.A. Todos  los  derechos  reservados.
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mIntroduction
Over  the  last  few  years,  there  has  been  major  progress  in
the  understanding  of  the  molecular  mechanism  associated
with  normal  haematopoiesis  and  with  the  development  of
haematological  neoplasias.1,2 The  molecular  alterations  in
genes  that  control  cell  differentiation  programs,  such  as
proto-oncogenes  and  tumour  suppressor  genes,  derive  in  the
loss  of  homeostasis  regulation  in  haematopoietic  tissue  and
promote  the  development  of  leukaemia.3 There  are  cur-
rently  over  50  different  chromosomal  alterations  associated
with  leukaemia.4--6 The  most  common  damage  mechanisms
are  the  balanced  chromosomal  translocations.  A  number
of  times,  there  are  genes  involved  in  chromosomal  translo-
cations  in  which  the  products  are  transcription  factors
that  control  differentiation  mechanisms  in  haematopoietic
tissue  precursor  cells.5--7 These  transcription  factors  are
responsible  for  the  malignant  transformation,  and  they  are
e
3
issential  elements  in  the  design  of  alternative  treatment
lans.8,9 Other  molecular  alterations  that  take  place  in  the
evelopment  of  leukaemia  are  those  called  point  mutations,
hich  damage  the  mechanisms  that  regulate  cell  prolif-
ration,  apoptosis  and  differentiation  in  haematopoietic
recursors.10,11 Lastly,  there  are  additional  alterations  that
o  not  affect  the  information  held  in  the  DNA  nucleotide
equence,  which  are  associated  with  epigenetic  events;
hat  is  to  say,  they  lead  to  DNA  hypermethylation  or  to
bnormal  histone  acetylation,  affecting  the  transcriptional
vailability  of  proto-oncogenes  and  suppressor  genes.12,13
exico  does  not  have  a  tumour  marker  panel  that  could  be
sed  to  perform  the  diagnosis,  prognosis  and  follow-up  for
eukaemia,  both  acute  and  chronic,  by  means  of  molecular
ethods  such  as  the  RT-PCR.  Our  laboratory  analysed  the
xpression  of  11  tumour  markers  in  mononuclear  cells  from
0  patients  with  leukaemia.  The  genes  under  analysis  are
nvolved  in  the  proliferation,  differentiation,  epigenetic
80  R.  Cerón-Maldonado  et  al.
Table  1  Sequence  of  the  primers  used  and  their  thermal  proﬁles.
Marker  Forward  oligonucleotide  Reverse  oligonucleotide  Product
length  (bp)
Ampliﬁcation  conditions
GAPDH  CGGGAAGCTTGTCATCAATGG  CATGGTTCACACCCATGACG  221  92 ◦C,  45′′, 60 ◦C,  45′′,
72 ◦C,  45′′ (35  cycles)
Beta CCTCCATGATGCTGCTTACATGTC  ATGTCTCGCTCCGTGGCCTTAGCT  397  92 ◦C,  45′′, 60 ◦C,  45′′,
72 ◦C,  45′′ (35  cycles)
BCR/ABL M  TGGAGCTGCAGATGCTGACCAACTCG  TGATTATAGCCTAAGACCCGAA  304  92 ◦C,  45′′, 60 ◦C,  45′′,
72 ◦C,  45′′ (35  cycles)
BCR/ABL m  ATCTCCACTGGCCACAAAATCATACA  AGATCTGGCCCAACGATGGCGAGGGC  196  92 ◦C,  45′′, 56 ◦C,  45′′,
72 ◦C,  45′′ (35  cycles)
E2A/PBX1 CCAGCCTCATGCACAACCA GGGCTCCTCGGATACTCAAAA 130  92 ◦C,  45′′, 60 ◦C,  45′′,
72 ◦C,  45′′ (35  cycles)
AF4/MLL GATGGAGTCCACAGGATCAGAGT  GAAAGGAAACTTGGATGGCTCA  156  92 ◦C,  45′′, 60 ◦C,  45′′,
72 ◦C,  45′′ (35  cycles)
TEL/AML CTCTGTCTCCCCGCCTGAA  CGGCTCGTGCTGGCAT  140  92 ◦C,  45′′, 60 ◦C,  45′′,
72 ◦C,  45′′ (35  cycles)
PML/RARA TCTTCCTGCCCAACAGCAA  GCTTGTAGATGCGGGGTAGAG  177  92 ◦C,  45′′, 60 ◦C,  45′′,
72 ◦C,  45′′ (35  cycles)
AML/ETO CACCTACCACAGAGCCATCAAA  ATCCACAGGTGAGTCTGGCATT  95  92 ◦C,  45′′, 61.7 ◦C,  45′′,
72 ◦C,  45′′ (35  cycles)
NY-ESO1 AAAAACACGGGCAGAAAGC  GCTTCAGGGCTGAATGGAT  308  92 ◦C,  1′,  60 ◦C,  45′′,
72 ◦C,  1′ (30  cycles)
MAGE A3  TGGAGGACCAGAGGCCCCC  GGACGATTATCAGGAGGCCTGC  725  92 ◦C,  1′,  67 ◦C,  45′′,
72 ◦C,  1′ (30  cycles)
ABC-B1 GCTCCTGACTATGCCAAAGC  CTTCACCTCCAGGCTCAGT  201  92 ◦C,  45′′, 60 ◦C,  45′′,
72 ◦C,  45′′ (35  cycles)
ABC-G2 CACCTTATTGGCCTCAGGAA CCTGCTTGGAAGGCTCTATG  206  92 ◦C,  45′′, 60 ◦C,  45′′,
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Rvents  and  resistance  mechanisms  to  drugs.  Among  the
enes  derived  from  translocations  are:  BCR-ABL  major  and
inor  breakpoint,  t(9;22),  E2A-PBX1,  t(1;19),  TEL-AML1
(12;21),  AF4-MLL  t(4;11),  AML1-ETO,  t(8;21),14--16 alter-
tions  that  take  place  due  to  changes  in  the  methylation
attern,  such  as  the  testicular  cancer  genes  that  are
nly  present  in  tumour  cells  and  absent  in  normal  tissue;
AGE-A3,  NY-ESO,  MAGE-4,17,18 and  genes  that  express  as
esistance  mechanisms  to  multiple  drugs,  such  as  ABC-B1
MDR-1)  and  ABC-G2  (BCR-P)  genes.19,20
The  results  showed  expression  of  the  tumour  markers
n  leukaemia  and  their  potential  use  for  the  diagnosis  and
rognosis  of  these  oncohaematologic  diseases.
ethodology
n  experimental,  prospective  study  was  carried  out  between
ebruary  and  December,  2014,  at  the  Molecular  and  Cell
iology  Department  of  the  Haematology  Service.  The  study
as  authorised  by  the  Institution’s  Research  and  Ethics  Com-
ittees.  30  patients  of  both  genders  with  ALL,  AML  and  de
ovo  CML  were  included  in  the  study.  Bone  marrow  aspira-
ion  was  performed  after  informed  consent  was  signed.ononuclear  cell  extraction
ononuclear  cells  were  extracted  using  Lymphoprep
NycomedPharma  AS,  Oslo,  Norway)  according  to  the
C
I
A72 ◦C,  45′′ (35  cycles)
upplier’s  instructions  and  stored  at  −80 ◦C  until  they  were
sed.
T-PCR
otal  cell  RNA  extraction  was  performed  through  Trizol
eactive  (Life  Technologies,  UK);  5  g  of  RNA  was  used  to
ynthesise  cDNA  through  MMLV  (Life  Technologies,  Paisley,
K).  CRP  ampliﬁcation  was  performed  using  speciﬁc  primers
Table  1).
Each  cDNA  was  tested  by  CRP  using  speciﬁc  primers  for
wo  genes  of  constitutive  expression  2 microglobulin  and
ADPH.  CRP  reaction  was  carried  out  according  to  the  align-
ent  temperature  previously  shown  in  Table  1. CRP  products
ere  visualised  in  2%  agarose  gel  dyed  with  Midori  Green
dvanced  (Nippon  Genetics,  Germany).
The  ampliﬁed  segments  were  sequenced  using  the  ABI
rism  Dye  Terminator  Cycle  Sequencing  kit.  The  alignment
as  performed  using  the  Gene-Bank  BLASTN  program,  gen-
rating  a  99%  similarity  with  all  the  biomarkers  used.
esultsharacteristics  of  the  patients
n  total,  30  patients  were  under  study;  10  of  each  type  (ALL,
ML,  CML),  the  median  age  for  each  group  was  of  32  for  ALL
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Table  2  Characteristics  of  the  patients  with  ALL.
N  (%)  Median  Minimum
Age  32  20--55
<35 5  (50)
≥35  5  (50)
Gender
Male  9  (90)
Female  1  (10)
Leukocytes  (×103/mm)  56.87  0.40--372.20
<30 4  (40)
≥30 6  (60)
HDL  (U/L) 586  149--3871
<500 3  (30)
≥500  7  (70)
Blast  cells  30.50  0--96
Hgb (g/dL)  8.25  3.40--14.10
Platelets  (×103/mm)  21  10--163
Splenomegaly
Yes 3 (30)
No  7  (70)
Hepatomegaly
Yes  3  (30)
No  7  (70)
Adenomegaly
Yes  5  (50)
No  5  (50)
Immunophenotype
Not  performed  5  (50)
B  lineage  5  (50)
Cytogenetics
Not  performed  10  (100)
Table  3  Characteristics  of  the  patients  with  AML.
N  (%)  Median  Range
Age  (years)  34  21--68
<35 4  (40)
≥35 6 (60)
Gender
Male  4  (40)
Female  6  (60)
Leukocytes  (×103/mm)  4.20  .90--166.30
<30 9  (90)
≥30 1  (10)
HDL (U/L)  322  137--785
<500 7  (70)
≥500  3  (30)
Blast  cells  --  0--58
Hgb (g/dL)  7.45  3.90--12.60
Platelets  (×103/mm)  19.50  9--114
Splenomegaly
Yes 1 (10)
No 9  (90)
Hepatomegaly
Yes 0
No 10  (100)
Adenomegaly
Yes 3  (30)
No 7  (70)
Immunophenotype
Not performed  6  (60)
Immature  myeloid  2  (20)
Mature  myeloid  2
Cytogenetics
Not  performed  7  (70)
Normal  2  (20)
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In  the  case  of  patients  with  AML,  the  biomarkers  identi-and  34  for  AML  and  CML.  Ages  ranged  between  20--55  years,
21--68  years  and  18--50  years,  respectively.
Regarding  ALL,  the  morphologic  classiﬁcation  corre-
sponded  to  type  L2,  70%  had  a  B-cell  immunophenotype.
Only  three  patients  had  hepatomegaly  and  one  of  them  had
high  levels  of  HDL,  hyperleukocytosis,  low  levels  of  platelets
(Table  2).
In the  group  of  patients  with  AML;  ﬁve  patients  were
AML-M3  (acute  promyelocytic  leukaemia),  four  were  AML-
M4  (acute  myelomonocytic  leukaemia)  and  one  was  AML-M2
(acute  myeloid  leukaemia  with  maturation).  60%  of  the
patients  were  over  the  age  of  60  and  only  one  reported  hav-
ing  hyperleukocytosis.  One  patient  had  splenomegaly  and
three  patients  had  adenomegaly.  As  for  the  cytogenetic
alterations,  only  one  patient  had  hyperdiploidy  (Table  3).
Lastly,  out  of  the  patients  with  CML,  60%  was  above  the
age  of  35,  100%  had  hyperleukocytosis,  and  eight  patients
had  high  levels  of  HDL.  80%  had  splenomegaly,  10%  had
hepatomegaly  and  only  10%  had  adenomegaly.  The  cytoge-
netic  alterations  reported  had  t(9;22)  only  among  10%  of  the
population  and  the  study  was  not  performed  in  90%  of  the
population  (Table  4).
ﬁ
P
(Hyperdiploidy  1  (10)
xpression  of  tumour  biomarkers  in  leukaemia
he  expression  of  11  cancer  biomarkers  was  analysed  (BCR-
BL  major,  minor,  ABC-B1,  ABC-G2,  E2A-PBX1,  AF4-MLL,
EL-AML1,  PML-RAR  alpha,  AML1-ETO,  NY-ESO,  MAGE-A3)  via
T-PCR  on  end-point  in  patients  with  ALL,  AML  and  CML.  The
uality  of  the  RNA  was  evaluated  by  means  of  the  ampliﬁca-
ion  of  the  genes  of  constitutive  expression  2  microglobulin
hat  ampliﬁes  an  expected  fragment  of  397  bp  and  GADPH  by
mplifying  a  221  bp  fragment.  The  markers  expressed  in  ALL
ere:  BCR-ABL  minor  breakpoint  with  an  ampliﬁcation  prod-
ct  of  196  bp,  detected  in  30%  (3/10),  ABC-B1  by  amplifying
 201  bp  fragment  in  80%  (8/10)  and  ABC-G2  with  a  206  bp
ragment  in  60%  (6/10).  In  addition,  the  expression  of  onco-
ene  E2A-PBX1  with  a  product  of  130  bp  was  detected  in  10%
1/10)  (Fig.  1).ed  were:  ABC-B1  in  40%  (4/10),  ABC-G2  in  10%  (1/10)  and
ML-RAR  alpha  with  an  ampliﬁed  product  of  177  bp  in  30%
3/10).  Lastly,  the  expression  of  biomarkers  detected  in  CML
82  R.  Cerón-Maldonado  et  al.
Table  4  Characteristics  of  the  patients  with  CML.
N  (%)  Median  Range
Age  (years)  34  18--50
<35 4  (40)
≥35  6  (60)
Gender
Male  9  (90)
Female  1  (10)
Leukocytes  (×103/mm)  273.40  102.09--524.30
≥30 10  (100)
HDL (U/L) 664.50  190.00--1125
<500 2
≥500  8
Blast  cells  2.00  .00--46
Hgb (g/dL)  10.80  6.40--13
Platelets  (×103/mm)  362.00  78.00--2013
Splenomegaly
Yes 8 (80)
No  2  (20)
Hepatomegaly
Yes  3  (30)
No  7  (70)
Adenomegaly
Yes  1  (10)
No  9  (90)
Cytogenetics
Normal  1  (10)
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Table  5  Frequency  of  the  panel  of  biomarkers  in
leukaemia.
Biomarker  ALL  AML  CML
N (%)  N  (%)  N  (%)
Major  BCR-ABL a a 10  (100)
Minor  BCR-ABL  3  (30) a  a
E2A-PBX1  1  (10) a  a
AF4-MLL a a a
TEL-AML1 a a a
PML-RAR a 3  (30) a
AML1-ETO a a a
NY-ESO1 a  a  a
MAGE-A3 a  a  a
ABC-B1  8  (80)  4  (40)  2  (20)
ABC-G2  6  (60)  1  (10)  5  (50)
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tt(9;22)  1  (10)
Not  performed  8  (80)
as  BCR-ABL  major  breakpoint  with  an  ampliﬁcation  frag-
ent  of  304  bp  in  100%  (10/10),  ABC-B1  in  20%  (2/10)  and
BC-G2  in  50%  (5/10)  (Table  5).
iscussionn  the  last  20  years,  several  molecular  methods  have  been
sed  to  detect  genetic  abnormalities  that  are  important
or  the  diagnosis  and  prognosis  of  leukaemias.21,22 Early
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igure  1  Representative  image  of  a  patient  with  LAL.  Lane
: Molecular  weight  marker;  Lane  2:  -2-microglobulin  (394  pb)
nd GAPDH  (221  pb);  Lane  3:  BCR-ABL  M  (−);  Lane  4:  BCR-ABL
 (150  pb);  Lane  5:  E2A-PBX1  (−);  Lane  6:  TEL-AML1  (−);  Lane
: AF4-MLL1  (−);  Lane  8:  PML-RAR  (−);  Lane  9:  AML1-ETO  (−);
ane10:  MAGE-A3  (−);  Lane  11:  NY-ESO1  (−);  Lane  12:  ABC-B1
201 pb);  Lane13:  ABC-G2  (206  pb).
m
c
i
n
O
a
r
A
A
c
b
o
i
a
A
b
n
p
d
aa Negative.
etection  is  essential  to  make  decisions  about  speciﬁc
reatments,  such  as  with  tyrosine  kinase  inhibitors  (Imat-
nib,  Nilotinib  or  Dasatinib),  used  in  patients  with  CML
nd  ALL  who  express  BCR-ABL  oncogenic  protein,  as  well
s  the  use  of  trans-retinoic  acid  used  in  patients  with
ML-M3  who  express  PML-RAR  alpha  protein.  These  treat-
ents  have  shown  a  survival  increment  of  up  to  80%  in  ﬁve
ears.23,24 We  searched  for  seven  tumour  markers  derived
rom  translocations,  BCR-ABL  major  and  minor,  E2A-PBX1,
F4-MLL,  TEL-AML1,  PML-RAR  alpha  and  AML1-ETO.  The
esults  showed  the  expression  of  BCR-ABL  minor  break-
oint  in  30%  of  ALL  and  E2A-PBX1  expression  in  10%;  these
esults  correspond  to  what  was  reported  previously.25,26 The
etection  of  BCR-ABL  in  patients  with  ALL  enables  us  to
elect  the  use  of  inhibitors  that  revert  the  development
f  the  disease.27 Regarding  AMLs,  the  expression  of  onco-
ene  PML-RAR  alpha  was  detected  in  30%  of  the  AML-M3,
hich  coincides  with  the  international  series.  Its  detection
s  essential  to  begin  treatment  with  trans-retinoic  acid.28
t  is  important  to  point  out  that  only  one  AML-M3  case  had
he  t(15;17)  by  cytogenetics,  from  which  the  PML-RAR  alpha
ranscript  is  derived.  In  the  case  of  CMLs,  only  the  BCR-ABL
ajor  breakpoint  expression  was  observed  in  100%,  which
oincides  with  what  was  reported  previously.  This  marker
s  fundamental  to  begin  treatment  with  Imatinib  or  Niloti-
ib,  and  it  increases  survival  in  up  to  80%  in  ﬁve  years.29,30
ur  panel  conﬁrms  the  clinical  diagnosis  was  performed  in
ll  cases.  Cell  resistance  to  chemotherapy  drugs  can  rep-
esent  the  main  cause  of  failure  of  current  treatments.31,32
s  for  the  expression  of  drug-resistant  genes,  ALLs  express
BC-B1  more  frequently,  followed  by  AMLs  and  CMLs.  In  the
ase  of  ABC-G2,  the  expression  is  higher  in  ALLs,  followed
y  CMLs  and  AMLs.  It  has  been  reported  that  the  percentage
f  healing  cases  in  ALLs  in  ﬁve  years  is  of  30%  and  in  AML
t  is  between  15  and  25%.33 Olarte  Carrillo  et  al.  reported
n  ABC-B1  frequency  of  expression  of  27.3%  in  patients  with
ML.  As  for  ALL,  the  frequency  varies  between  22  and  47%
y  protein  analysis.34,35 The  expression  at  the  time  of  diag-
osis  could  be  of  use  during  the  follow-up  treatment  and
rognosis  of  the  disease.  There  is  controversy  over  its  pre-
ictive  association.  Our  research  group  previously  reported
n  association  with  treatment  failure  in  22  patients  with
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AML.36,37 In  the  case  of  the  expression  of  genes  ABC-G2,
only  an  increment  in  malignant  progenitor  cells  derived  from
CML  has  been  reported.38 In  this  study,  an  increment  in  the
frequency  of  CML  and  ALL  was  found,  so  this  could  be  asso-
ciated  with  the  mechanisms  of  resistance  to  inhibitors.  In
the  case  of  the  biomarkers  involved  in  epigenetic  changes
like  MAGE  A3  and  NY-ESO-1,  there  was  no  sign  of  expression
in  any  of  the  analysed  samples.  Previously,  in  a  series  of  115
patients,  MAGE-A3  expression  was  found  in  41%  of  AML  and
30%  of  ALL,39 involved  in  the  progression  of  the  disease;  in
the  case  of  MAGE  A3,  we  have  detected  its  expression  in  46%
of  diffuse  large  B-cell  lymphomas  and  an  involvement  with
a  lower  survival  rate.17,40
In  conclusion,  the  panel  used  by  means  of  RT-PCR  enables
to  back  routine  methods  for  decision-making  in  treatments,
not  only  in  the  beginning  but  also  in  the  detection  of  the
minimal  residual  disease,  which  enables  assessment  of  the
tumour  load  in  a  precise  and  speciﬁc  manner.  Having  a  panel
of  11  standardised  markers  reduces  the  time  it  takes  to
arrive  at  a  diagnosis  of  oncohaematologic  diseases.  Knowing
the  frequency  of  expression  within  our  population  enables
us  to  have  timely  detection  and  control,  which  improves  the
performance  of  current  available  treatments.
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